Neurocrine Biosciences Inc (NBIX)
Pretax margin
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | 332,100 | 251,800 | 234,100 | 89,200 | 213,900 | 82,200 | 14,800 | 95,600 | 101,400 | 156,900 | 69,300 | 95,000 | 106,700 | 103,600 | 219,100 | 188,000 | 46,500 | 26,708 | 19,072 | -38,941 |
| Revenue (ttm) | US$ in thousands | 1,882,900 | 1,779,300 | 1,668,300 | 1,522,900 | 1,411,600 | 1,306,100 | 1,208,800 | 1,185,500 | 1,107,700 | 1,050,200 | 1,010,800 | 1,022,200 | 1,020,900 | 1,017,010 | 981,066 | 862,604 | 764,254 | 651,736 | 581,765 | 503,032 |
| Pretax margin | 17.64% | 14.15% | 14.03% | 5.86% | 15.15% | 6.29% | 1.22% | 8.06% | 9.15% | 14.94% | 6.86% | 9.29% | 10.45% | 10.19% | 22.33% | 21.79% | 6.08% | 4.10% | 3.28% | -7.74% |
December 31, 2023 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $332,100K ÷ $1,882,900K
= 17.64%
Neurocrine Biosciences, Inc.'s pretax margin has exhibited variability over the past eight quarters. The company's pretax margin has shown an increasing trend from Q1 2022 to Q2 2023, with Q4 2023 having the highest pretax margin at 17.60%. This indicates that Neurocrine Biosciences, Inc. has been able to generate more income before taxes relative to its revenue in the most recent quarter.
The company experienced fluctuations in its pretax margin performance, with significant increases in Q4 2022, Q3 2023, and Q4 2023, indicating periods of improved profitability. It is worth noting that Neurocrine Biosciences, Inc. showed a notable decline in pretax margin in Q1 2023 and Q2 2023 compared to the previous quarters, which could be a concern for stakeholders.
Overall, Neurocrine Biosciences, Inc. has demonstrated the ability to manage its expenses and generate profits before tax, although further analysis of the factors influencing the fluctuations in pretax margin would be necessary to provide a more in-depth understanding of the company's financial performance.
Peer comparison
Dec 31, 2023